New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
04:55 EDTDHR, DHR, DHR, TEVA, TEVA, TEVA, GMED, GMED, GMED, RHHBY, RHHBY, RHHBY, MDCO, MDCO, MDCO, NVO, NVO, NVO, GILD, GILD, GILD, OMI, OMI, OMI, PKI, PKI, PKI, WCG, WCG, WCG, BDX, BDX, BDXGoldman to hold a conference
35th Annual Global Healthcare Conference to be held in Rancho Palos Verdes, California on June 10-12.
News For DHR;WCG;PKI;OMI;GILD;NVO;MDCO;RHHBY;GMED;TEVA;BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 24, 2015
10:20 EDTTEVATeva says EMA confirms validation of reslizumab MAA
Subscribe for More Information
August 23, 2015
12:35 EDTRHHBYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
05:51 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 25, Keurig Green Mountain (GMCR) 39 according to iVolatility.
August 20, 2015
16:34 EDTGILDGilead MAA for HIV regimen has been fully validated by EMA
Gilead Sciences announced that the company's Marketing Authorization Application, MAA, for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg has been fully validated and is now under evaluation by the European Medicines Agency, EMA. Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data included in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older. "With this validation, R/F/TAF is now the third TAF-based filing under review by the EMA as we advance a portfolio of new treatment options that may offer high efficacy and favorable safety profiles," said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. "The R/F/TAF filing also represents the next step in our collaboration with Janssen to develop HIV treatments that potentially meet the diverse needs of people living with HIV."
11:45 EDTDHRKeysight Technologies soars after Q3 results, FY15 guidance top estimates
Subscribe for More Information
11:33 EDTNVOLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
05:58 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 23, Keurig Green Mountain (GMCR) 37 according to iVolatility.
05:57 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Subscribe for More Information
August 19, 2015
06:08 EDTBDXFDA warns 'do not use' compounded drugs stored in BD 3ml, 5ml syringes
Subscribe for More Information
August 18, 2015
08:04 EDTTEVATeva shares reflect Copaxone franchise risk, says Morgan Stanley
Subscribe for More Information
07:57 EDTWCGMagellan Iowa loss largely priced into shares, says Jefferies
Subscribe for More Information
August 17, 2015
16:12 EDTWCGMagellan drops after Iowa picks four others for Medicaid
Subscribe for More Information
15:56 EDTWCGWellCare up 4.5% after being awarded Iowa healthcare contract
Subscribe for More Information
15:55 EDTWCGWellCare, Amerigroup, UnitedHealth, AmeriHealth awarded Iowa healthcare contract
Reference Link
05:14 EDTRHHBYGenentech reports atezolizumab pivotal Phase II study met primary endpoint
Subscribe for More Information
August 14, 2015
17:17 EDTGILDPoint72 gives quarterly update on stakes
Subscribe for More Information
17:08 EDTTEVAPaulson & Co gives quarterly update on stakes
Subscribe for More Information
10:21 EDTNVONovo Nordisk management to meet with Jefferies
Subscribe for More Information
06:39 EDTNVOGenmab enters commercial license agreement with Novo Nordisk
Genmab (GNMSF) announced it has entered an agreement to grant Novo Nordisk (NVO) commercial licenses to use the DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs. The bispecific antibodies will target a disease area outside of cancer therapeutics. Under the terms of the agreement, Genmab will receive an upfront payment of $2M from Novo Nordisk. After an initial period of exclusivity for the two target combinations, Novo Nordisk has an option to maintain exclusivity or take the licenses forward on a non-exclusive basis. Genmab is entitled to potential development, regulatory and sales milestones of up to approximately $250M for each exclusive license, or approximately $200M for each non-exclusive license. In addition, Genmab will be entitled to single-digit royalties on sales of any commercialized products.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use